A 32-year-old woman presents with severe dysmenorrhea and chronic pelvic pain for 18 months. Imaging shows multiple chocolate cysts in both ovaries with peritoneal adhesions. She has failed NSAIDs and wishes to defer surgery. What is the drug of choice for medical management of her endometriosis?

Explanation

## First-Line Medical Management of Endometriosis **Key Point:** Gonadotropin-releasing hormone (GnRH) agonists like leuprolide acetate are the gold-standard medical therapy for moderate-to-severe endometriosis when surgery is deferred or has failed. ### Mechanism of Action GnRH agonists cause initial flare (increased FSH/LH), followed by downregulation of the pituitary and profound suppression of estrogen production. This creates a hypoestrogenic state that arrests endometrial growth and promotes regression of ectopic endometrial tissue. ### Clinical Efficacy in Endometriosis - **Pain relief:** 80–90% of patients experience significant reduction in dysmenorrhea and chronic pelvic pain - **Lesion regression:** Documented shrinkage of chocolate cysts and adhesions on repeat imaging - **Duration:** Typically 3–6 months of therapy; can be extended up to 12 months with add-back hormone therapy (HT) to mitigate hypoestrogen side effects ### Add-Back Hormone Therapy When using GnRH agonists beyond 6 months, concurrent low-dose estrogen + progestin (or progestin alone) is recommended to prevent: - Vasomotor symptoms (hot flushes) - Vaginal dryness - Bone loss (osteoporosis risk) **Clinical Pearl:** Add-back therapy does NOT reduce efficacy of the GnRH agonist for endometriosis control, but significantly improves tolerability and safety. ### Comparison with Other Agents | Agent | Role in Endometriosis | Limitation | |-------|----------------------|------------| | **Leuprolide (GnRH agonist)** | Gold standard for moderate–severe disease | Hypoestrogen side effects; cost | | **Danazol** | Older androgenic agent; rarely used now | Virilization, lipid abnormalities, poor tolerability | | **Mifepristone** | Experimental; not approved for endometriosis | Limited evidence; not standard of care | | **Methotrexate** | No role in endometriosis management | Immunosuppressant; not indicated | **High-Yield:** GnRH agonists are preferred over progestins in severe endometriosis with large cysts because they achieve faster and more complete suppression of estrogen-driven lesion growth. ### Why GnRH Agonists Are Superior Here This patient has: - **Moderate-to-severe disease** (multiple bilateral cysts + adhesions) - **Failed conservative therapy** (NSAIDs ineffective) - **Desire to defer surgery** GnRH agonists offer the highest likelihood of symptom relief and lesion regression in this scenario. [cite:Berek & Novak's Gynecology 16e Ch 12]